Effects of Alemtuzumab on Umbilical Cord Blood Stem Cells
Author Information
Author(s): Lim Che K, Sun Li, Feng Qi, Law Ping, Chua Wei T, Lim Shy N, Hwang William YK
Primary Institution: Singapore General Hospital
Hypothesis
Depletion of CD52+ cells with alemtuzumab may lead to a higher percentage of CD34+ cells during ex vivo expansion of cord blood.
Conclusion
The use of alemtuzumab for ex vivo expansion of cord blood hematopoietic stem cells may be beneficial, potentially improving the availability of cord blood units for transplantation.
Supporting Evidence
- The addition of alemtuzumab resulted in a significant increase in total nucleated cells and absolute CD34+ cells.
- Alemtuzumab led to a 98.48% reduction in CD52+ cells and a 96.36% reduction in CD90+ lymphoid progenitors.
- CFU-GEMM and CFU-GM were significantly improved with alemtuzumab treatment.
- LTC-IC numbers were preserved with alemtuzumab, confirming retention of hematopoietic progenitors.
- Secondary cultures showed a higher percentage of CD34+ cells with alemtuzumab compared to controls.
Takeaway
This study found that a drug called alemtuzumab helps grow more important blood cells from umbilical cord blood, which could help more people get transplants.
Methodology
Ex vivo expansion experiments were conducted using purified cord blood CD34+ cells in specific culture conditions with alemtuzumab to deplete CD52+ cells.
Potential Biases
Potential bias in the selection of cord blood units that did not meet banking criteria.
Limitations
The study primarily focused on ex vivo conditions and may not fully predict in vivo outcomes.
Participant Demographics
Cord blood samples were obtained from the Singapore Cord Blood Bank.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website